Introduction
============

Tamoxifen (TAM) is a selective receptor modulator and has been used in hormone therapy for the prophylaxis and adjuvant and neoadjuvant treatment in breast cancer. It expresses a potent estrogenic antagonist effect on the estrogen receptor (ER) by competing with estrogen for binding to the ER and preventing cell growth[@b1-bctt-8-149] in ER-positive breast cancer patients. Despite the fact that TAM provides significant clinical benefit, interindividual variability in its metabolism and effectiveness has been linked to single nucleotide polymorphisms (SNPs) in the genes encoding cytochrome P450 (CYP450) enzymes that are involved in TAM-metabolic pathways.[@b2-bctt-8-149]--[@b5-bctt-8-149] CYP2D6 and CYP3A5 are the main CYP450 enzymes involved in the transformation of TAM from its conventional prodrug form to the active metabolites endoxifen (END) and *4*-hydroxy-tamoxifen (4OHT) ([Figure 1](#f1-bctt-8-149){ref-type="fig"}).[@b1-bctt-8-149],[@b6-bctt-8-149],[@b7-bctt-8-149] Several studies have investigated the associations between polymorphisms in these two enzyme encoded genes and the clinical outcomes of breast cancer[@b3-bctt-8-149],[@b5-bctt-8-149],[@b8-bctt-8-149]--[@b15-bctt-8-149] or the concentration of TAM and its metabolites ([Figure 2](#f2-bctt-8-149){ref-type="fig"}).[@b14-bctt-8-149],[@b16-bctt-8-149]--[@b19-bctt-8-149] However, routine pharmacogenetic testing has not been suggested due to the inconclusive results obtained.[@b20-bctt-8-149],[@b21-bctt-8-149] These variations may result from differences in genotyping comprehensiveness, the DNA source, and the sample size. Nevertheless, previous studies revealed that the incomplete functional *CYP2D6\*4* and *CYP3A5\*3* alleles showed completely reduced enzyme activity, while *CYP2D6\*10* decreased its encoded enzyme function.[@b22-bctt-8-149],[@b23-bctt-8-149] The prevalence of these defective alleles was found to differ among racial populations. Thus, *CYP2D6\*4* was more prevalent in Caucasians than in Asians or Thais and *CYP2D6\*10* was more frequent in Asians ([Table 1](#t1-bctt-8-149){ref-type="table"}).[@b8-bctt-8-149],[@b14-bctt-8-149],[@b16-bctt-8-149],[@b24-bctt-8-149] *CYP3A5\*3* was the major allele in Caucasians and Asians, while *CYP3A5\*1* was the major allele in Thai populations ([Table 1](#t1-bctt-8-149){ref-type="table"}).[@b9-bctt-8-149],[@b14-bctt-8-149],[@b24-bctt-8-149] Thai patients with *CYP2D6\*10/\*10* had a lower END level than those patients with *CYP2D6\*1/\*10* and *CYP2D6\*1/\*1* (*P*=0.045)[@b16-bctt-8-149] and had a shorter disease-free survival than heterozygous *CYP2D6\*10* or other genotypes (*P*=0.046).[@b8-bctt-8-149] Previous studies have revealed the relationships between these gene polymorphisms and the clinical outcomes in Thai breast cancer patients.[@b8-bctt-8-149],[@b9-bctt-8-149],[@b16-bctt-8-149] These results emphasize the opportunity to improve the pharmacological effectiveness of TAM, which is the most prescribed antihormone therapy for breast cancer treatment in Thailand. However, these studies were limited by their small sample sizes. The main objective of the present study was to determine the prevalence of the *CYP2D6\*2*, *CYP2D6\*4*, *CYP2D6\**10, and *CYP3A5\*3* defective alleles in a larger sample size of Thai breast cancer patients undergoing TAM treatment.

Patients and methods
====================

Patient recruitment and sample preparation
------------------------------------------

Thai breast cancer patients who were taking TAM at 20 mg once daily and who visited the oncology outpatient clinic at King Chulalongkorn Memorial Hospital between February and March 2015 were randomly invited to join the Thai Tamoxifen Project. All patients were at least 18 years old with normal hepatic and renal functions (upper normal limit of aspartate aminotransferase and alanine aminotransferase δ2, serum creatinine δ1.2 mg/dL) in the 4 weeks prior to recruitment. Patients who were diagnosed for psychiatric illness or cognitive impairment were excluded from the study. For the remaining 134 patients who formed this study group, 10 mL of whole blood was drawn from each patient by a professional nurse and stored in a Vacutainer^®^ K~2~EDTA tube (BD, Franklin Lakes, NJ, USA). DNA extraction was prepared from the buffy coat using a QIAamp^®^ DNA Mini Kit (Qiagen NV, Venlo, the Netherlands). All DNA samples were stored at −20°C until analysis. The study protocol was approved by the Institutional Review Board of the Faculty of Medicine, Chulalongkorn University (IRB No 406/57). All patients provided written informed consent.

Genotype, phenotype, and data analysis
--------------------------------------

The genotype analysis was performed by real-time polymerase chain reaction (PCR) with TaqMan^®^ Universal PCR Master Mix and TaqMan^®^ Drug Metabolism Genotyping Assay Mix (*CYP2D6\*2*, *CYP2D6\*10* and *CYP3A5\*3*) with StepOnePlus^®^ real-time PCR and Vii7 software (Thermo Fisher Scientific, Waltham, MA, USA). The PCR thermal cycling was performed as follows: 60°C for 30 seconds and 95°C for 10 minutes, and then, 40 cycles of 95°C for 15 seconds and 60°C for 1 minute before a final 60°C for 30 seconds. The rs numbers of *CYP2D6\*2*, *CYP2D6\*10*, and *CYP3A5\*3* were rs16947 (2850C\>T), rs1065852 (100C\>T), and rs776746 (6986A\>G), respectively. *CYP2D6\*4* was determined by considering the haplotype of *CYP2D6\*2* (2850C\>T) with *CYP2D6\*10* (100C\>T). Phenotypes were classified as extensive metabolizer (EM) for normal enzyme activity and intermediate metabolizer (IM) and poor metabolizer (PM) for decreased and completely reduced enzyme activities, respectively ([Table 2](#t2-bctt-8-149){ref-type="table"}).[@b22-bctt-8-149] Data analysis was conducted by descriptive statistics using the SPSS software (Version 22; IBM Corporation, Armonk, NY, USA).

Results
=======

A total of 134 Thai breast cancer women undergoing TAM treatment formed the study group. Most of them were in the early stage of breast cancer (32.8% and 43.3% in stages I and II, respectively). Their mean age, weight, and BMI were 51.6±11.6 years (range 27.0--82.0 years), 60.0±10.7 kg (range 36.0--107.5 kg), and 24.0±4.3 (range 15.4--40.0), respectively. Their ER and progesterone receptor (PR) statuses were ER+/PR+ (71.6%), ER+/PR− (26.9%), ER−/PR+ (0.75%), and ER−/PR− (0.75%). The proportion of premenopausal patients (53%) was higher than the postmenopausal (36.6%) ones in this study group. Some patients had been treated with other breast cancer treatments before they received TAM, while nine patients (6.7%) had used TAM as monotherapy for breast cancer. The median duration of receiving TAM treatment was 17.2 months (interquartile range 16.1 months; range 0.8--62.1 months; [Table 3](#t3-bctt-8-149){ref-type="table"}). Of these 134 patients, the allelic frequencies of *CYP2D6\*1*, *CYP2D6\*2*, *CYP2D6\*4*, *CYP2D6\*10*, *CYP3A5\*1*, and *CYP3A5\*3* were 72.9%, 3.2%, 1.1%, 22.8%, 37.3%, and 62.7%, respectively. *CYP2D6\*10/\*10* and *CYP3A5\*1/\*3* were the most common genotypes found in this study at 53.7% and 47.8%, respectively ([Table 4](#t4-bctt-8-149){ref-type="table"}). In total, 131 patients (97.8%) had at least one defective allele (*CYP2D6\*4*, *CYP2D6\*10*, and *CYP3A5\*3*) that included 28 patients (20.9%) who had only defective alleles for both the *CYP2D6* and *CYP3A5* genes (25 patients with *CYP2D6\*10/\*10* and *CYP3A5\*3/\*3*, two patients with *CYP2D6\*4/\*4* and *CYP3A5\*3/\*3*, and one patient with *CYP2D6\*4/\*10* and *CYP3A5\*3/\*3*), which was potentially responsible for their low enzyme activities compared with those patients who were carrying at least one normal functional allele (*CYP2D6\*1*, *CYP2D6\*2*, and *CYP3A5\*1*).

Moreover, the prevalence of the *CYP2D6* phenotype was 41.0%, 57.5%, and 1.5% in the EM, IM, and PM enzyme activity categories, respectively, while the prevalence of the *CYP3A5* phenotype was 61.2% and 38.8% for EM and PM, respectively. Note that *CYP3A5*-IM was not found in this study ([Table 4](#t4-bctt-8-149){ref-type="table"}). Furthermore, only 31 patients (23.1%) were categorized as EM for both the *CYP2D6* and *CYP3A5* genes, while the others (75.37%) were IM or PM for at least one gene, including the two patients (1.5%) who were PM for both the *CYP2D6* and *CYP3A5* genes ([Table 5](#t5-bctt-8-149){ref-type="table"} and [Figure 3](#f3-bctt-8-149){ref-type="fig"}).

Discussion
==========

Prevalence of wild-type and mutant alleles including their genotypes was different depending on the racial origin of population ([Table 1](#t1-bctt-8-149){ref-type="table"}). However, the prevalence of these alleles was also different within the same population among studies. First, that the 9.7% frequency of the *CYP2D6\*1/\*1* allele in Thai breast cancer patients found in this research is lower than the prevalence previously reported[@b16-bctt-8-149] is probably the result of the simultaneous *CYP2D6\*2* determination. Previously, Areepium et al[@b16-bctt-8-149] used only the *CYP2D6\*10* (100C\>T) assay to discriminate the *CYP2D6\*10* SNP from the *CYP2D6\*1* wild type based on the quantitative PCR technique with the TaqMan^®^ assay, while Chamnanphon et al[@b8-bctt-8-149] used the AmpliChip™ CYP450 test that can detect several SNPs simultaneously, including *CYP2D6\*2* (2549delA), *CYP2D6\*4* (1846G\>A), and *CYP2D6\*10* (100C\>T).[@b25-bctt-8-149] The prevalence of *CYP2D6\*1/\*1* that was reported in these studies, therefore, depended on the number and position of SNPs that were included in each respective analytical platform, which varied among the three studies. Second, the higher prevalence of *CYP2D6\*10/\*10* found in this study compared with previous studies in Thai breast cancer patients might be due to the larger number of patients who were recruited in this study. More patients helped identifying rare genotypes (*CYP2D6\*4/\*4* and *CYP2D6\*4/\*10*) that were not reported from the previous study ([Table 1](#t1-bctt-8-149){ref-type="table"}).[@b8-bctt-8-149] However, the summation of these genotype frequencies with fully functional alleles (*CYP2D6\*1/\*1*, *CYP2D6\*1/\*2*, and *CYP2D6\*2/\*2*) was 15.6%, which agreed with the previous studies.[@b8-bctt-8-149],[@b16-bctt-8-149] Determination of the *CYP2D6\*2* allele was useful for separating *CYP2D6\*2/\*10* (EM), *CYP2D6\*4/\*4* (PM), and *CYP2D6\*4/\*10* (IM) from *CYP2D6\*1/\*10* (EM), which was responsible for the low reported prevalence of *CYP2D6\*1/\*10* (15.7%) in this study compared with the previous ones.[@b8-bctt-8-149],[@b16-bctt-8-149] The *CYP2D6\*4/\*4* and *CYP2D6\*4/\*10* alleles would potentially contribute to the low enzyme activities compared with *CYP2D6\*10/\*10* allele and might differentially affect the concentration of TAM and its metabolites. There were seven patients whose genotypes were classified as *CYP2D6\*4* instead of *CYP2D6\*10* according to the simultaneous use of the *CYP2D6\*2* assay ([Table 6](#t6-bctt-8-149){ref-type="table"}). Gaedigk et al[@b26-bctt-8-149] and Lyon et al[@b25-bctt-8-149] suggested that the 100C\>T SNP occurred on both the *CYP2D6\*4* and *CYP2D6\*10* alleles but they could be assigned during the absence of 1846G\>A for the *CYP2D6\*4* allele.[@b25-bctt-8-149],[@b26-bctt-8-149]

The 1846G\>A SNP was not used in this study due to the low prevalence of the *CYP2D6\*4* allele in Thai population, but the *CYP2D6\*4* allele was detected in this study by considering the haplotypes of 100C\>T with 2850C\>T,[@b25-bctt-8-149] which were detected by the *CYP2D6\*10* and *CYP2D6\*2* assays, respectively. The *CYP2D6\*2* determination showed the following benefits in this study. First, the *CYP2D6\*2* assay helped to give a more accurate estimate of the prevalence of the *CYP2D6\*2* allele by discriminating between *CYP2D6\*2* and *CYP2D6\*1*, the latter of which is another *CYP2D6* wild type allele reported in Thai patients.[@b8-bctt-8-149] Second, the *CYP2D6\*2* determination revealed the *CYP2D6\*2/\*10*, *CYP2D6\*4/\*4*, and *CYP2D6\*4/\*10* genotypes, which have not been discovered by applying only the *CYP2D6\*10* assay. Third, the *CYP2D6\*4/\*4* and *CYP2D6\*4/\*10* alleles were found in this study, which potentially contributed to the different enzyme activities compared with *CYP2D6\*1/\*10*.

The prevalence of *CYP2D6\*10* was high in Thais, while the prevalence of *CYP2D6\*4* was high in Caucasians[@b24-bctt-8-149] ([Table 1](#t1-bctt-8-149){ref-type="table"}), which subsequently raised *CYP2D6\*10/\*10* to be the most common genotype in this study. This finding disagrees with the study in Caucasians that the *CYP2D6\*10/\*10* allele has not been reported ([Table 7](#t7-bctt-8-149){ref-type="table"}).[@b24-bctt-8-149] Moreover, the prevalence of the *CYP3A5\*1/\*3* and *CYP3A5\*3/\*3* alleles was also high in this study (47.8% and 38.8%, respectively) compared with *CYP3A5\*1/\*1* (13.4%), which is in accordance with the previous studies in Caucasian[@b24-bctt-8-149] and Asian[@b14-bctt-8-149] populations ([Tables 1](#t1-bctt-8-149){ref-type="table"} and [7](#t7-bctt-8-149){ref-type="table"}) but disagrees with a previous report that the *CYP3A5\*1/\*1* allele was the most common *CYP3A5* genotype in Thai breast cancer patients.[@b9-bctt-8-149] This disagreement might reflect the limited number of patients recruited in that study (30 patients) compared with the other studies.[@b14-bctt-8-149],[@b24-bctt-8-149] Furthermore, the low prevalence of the *CYP3A5\*1/\*1* allele reported in Thai and Asian populations was due to the high prevalence of *CYP3A5* polymorphisms in both Caucasians and Asians, including Thais. Moreover, it was found that 20.9% of these patients had only defective alleles, including the two patients who were PM for both *CYP2D6* and *CYP3A5* genes. Thus, Thai breast cancer patients undergoing TAM treatment potentially have a risk for a low activity of the enzymes involved in the TAM-metabolic pathway, especially for the CYP2D6 and CYP3A5 enzymes that are responsible for END formation.

This study had some limitations. The frequency of the *CYP2D6\*4* allele was determined by considering the *CYP2D6\*2* (2850C\>T) and *CYP2D6\*10* (100C\>T) haplotypes without using the *CYP2D6\*4* (1846G\>A) assay. According to the reported low prevalence of *CYP2D6\*4* in Thai breast cancer patients,[@b8-bctt-8-149] these genotypes were classified as *CYP2D6\*2/\*10.* There were 13 patients (9.7%) who expressed *CYP2D6\*1/\*2* (*CYP2D6\*2* assay) with *CYP2D6\*1/\*10* (*CYP2D6\*10* assay) that were possibly carrying *CYP2D6\*2/\*10* (2850C\>T and 100C\>T were located on different alleles) or *CYP2D6\*1/\*4* (2850C\>T and 100C\>T were located on the same allele). These genotypes were classified as *CYP2D6\*2/\*10* in this study due to the low prevalence of *CYP2D6\*4* in Thai patients.[@b8-bctt-8-149] However, further investigations need to be performed to explore other possible allele patterns and confirm the genotype classification results of this study.

Conclusion
==========

This research indicated a high prevalence of the *CYP2D6* and *CYP3A5* defective alleles in Thai breast cancer patients undergoing TAM treatment. Future studies should be focused on the concentration of TAM and its metabolites to reveal the true effect of the enzymes encoded by these gene polymorphisms on TAM treatment, which could be further applied for drug therapy monitoring in clinical settings.
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![TAM-metabolic pathways and selected CYP450 enzymes.\
**Notes:** TAM was metabolized by CYP450 enzyme to its active metabolites: END and 4OHT. END was created via NDMT and 4OHT.\
**Abbreviations:** TAM, tamoxifen; CYP450, cytochrome P450; END, endoxifen; 4OHT, *4*-hydroxy-tamoxifen; NDMT, *N*-desmethyl tamoxifen.](bctt-8-149Fig1){#f1-bctt-8-149}

![A diagram of *CYP2D6*, *CYP3A5* polymorphisms, and breast cancer outcomes from previous research.\
**Abbreviations:** TAM, tamoxifen; NDMT, N-desmethyl-tamoxifen; 4OHT, *4*-hydroxy-tamoxifen; END, endoxifen; OS, overall survival; PFS, progress-free survival; CB, clinical benefit; IDFS, invasive disease-free survival; DFS, disease-free survival.](bctt-8-149Fig2){#f2-bctt-8-149}

![Prevalence of combined *CYP2D6* and *CYP3A5* phenotype in Thai breast cancer patients undergoing TAM treatment (N=134).\
**Notes:** Outer arrow line indicates prevalence of combined *CYP2D6* and *CYP3A5* phenotype. Outer doughnut chart indicates prevalence of *CYP2D6* phenotype. Inner doughnut chart indicates prevalence of *CYP3A5* phenotype.\
**Abbreviations:** TAM, tamoxifen; EM, extensive metabolizer; PM, poor metabolizer; IM, intermediate metabolizer.](bctt-8-149Fig3){#f3-bctt-8-149}

###### 

Prevalence of *CYP2D6* and *CYP3A5* polymorphisms in Caucasians, Asians, and Thais

  Allele/genotype   Prevalence (%)                                         
  ----------------- ----------------------- ------------------------------ ---------------------------------------------
  *CYP2D6*                                                                 
   *\*1*            76.7[@b24-bctt-8-149]   49.0--100.0[@b14-bctt-8-149]   35.0[@b8-bctt-8-149]--47.0[@b16-bctt-8-149]
   *\*2*            0.0[@b24-bctt-8-149]    19.0[@b14-bctt-8-149]          9.6[@b8-bctt-8-149]
   *\*4*            11.7[@b24-bctt-8-149]   \<1.0[@b14-bctt-8-149]         0.9[@b8-bctt-8-149]
   *\*10*           0.4[@b24-bctt-8-149]    51.0[@b14-bctt-8-149]          53.0[@b16-bctt-8-149]
   *\*1/\*1*        63.9[@b24-bctt-8-149]   30.2--100.0[@b14-bctt-8-149]   15.7[@b8-bctt-8-149]--27.1[@b16-bctt-8-149]
   *\*1/\*2*        0.0[@b24-bctt-8-149]    26.6[@b14-bctt-8-149]          3.5[@b8-bctt-8-149]
   *\*2/\*2*        0.0[@b24-bctt-8-149]    7.2[@b14-bctt-8-149]           3.5[@b8-bctt-8-149]
   *\*1/\*4*        15.0[@b24-bctt-8-149]   0.7[@b14-bctt-8-149]           0.0[@b8-bctt-8-149]
   *\*4/\*4*        1.5[@b24-bctt-8-149]    0.0[@b14-bctt-8-149]           0.0[@b8-bctt-8-149]
   *\*2/\*4*        0.0[@b24-bctt-8-149]    0.0[@b14-bctt-8-149]           1.8[@b8-bctt-8-149]
   *\*1/\*10*       0.0[@b24-bctt-8-149]    38.9[@b14-bctt-8-149]          39.0[@b16-bctt-8-149]
   *\*2/\*10*       0.0[@b24-bctt-8-149]    0.0[@b14-bctt-8-149]           7.0[@b8-bctt-8-149]
   *\*4/\*10*       0.75[@b24-bctt-8-149]   0.0[@b14-bctt-8-149]           0.0[@b8-bctt-8-149]
   *\*10/\*10*      0.0[@b24-bctt-8-149]    30.9[@b14-bctt-8-149]          33.9[@b16-bctt-8-149]
  *CYP3A5*                                                                 
   *\*1*            2.2[@b24-bctt-8-149]    30.0[@b14-bctt-8-149]          80.0[@b9-bctt-8-149]
   *\*3*            97.8[@b24-bctt-8-149]   70.0[@b14-bctt-8-149]          20.0[@b9-bctt-8-149]
   *\*1/\*1*        0.0[@b24-bctt-8-149]    8.5[@b14-bctt-8-149]           63.0[@b9-bctt-8-149]
   *\*1/\*3*        4.4[@b24-bctt-8-149]    43.6[@b14-bctt-8-149]          33.0[@b9-bctt-8-149]
   *\*3/\*3*        95.6[@b24-bctt-8-149]   47.9[@b14-bctt-8-149]          4.0[@b9-bctt-8-149]

**Note:** Adapted from Copyright © 2013. *PLoS One*. Fernández-Santander A, Gaibar M, Novillo A, et al. Relationship between genotypes SULT1A2 and CYP2D6 and tamoxifen metabolism in breast cancer patients. 2013;8(7):e70183.[@b24-bctt-8-149] © 2011 The Authors. *British Journal of Clinical Pharmacology* © 2011. The British Pharmacological Society. Lim JS, Chen XA, Singh O, et al. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. 2011;71(5):737--750.[@b14-bctt-8-149]

###### 

Phenotype classification by the conventional method

  Genotype                Phenotype   Genotype          Phenotype
  ----------------------- ----------- ----------------- -----------
  Functional/functional   EM          Reduced/reduced   IM
  Functional/reduced      EM          Reduced/null      IM
  Functional/null         EM          Null/null         PM

**Notes:** Functional alleles = *CYP2D6\*1*, *CYP2D6\*2*, and *CYP3A5\*1*. Reduced allele = *CYP2D6\*10*. Null alleles = *CYP2D6\*4* and *CYP3A5\*3*.

**Abbreviations:** EM, extensive metabolizer; IM, intermediate metabolizer; PM, poor metabolizer.

###### 

Demographic data of Thai breast cancer patients undergoing TAM treatment

  Demographic and clinical data   N (%)
  ------------------------------- ------------
  Age (years)                     
   18--30                         1 (0.7)
   30--40                         17 (12.7)
   40--50                         54 (40.3)
   \>50                           62 (46.3)
  TAM administration (years)      
   \<0.5                          26 (19.4)
   0.5--1                         23 (17.2)
   1--3                           57 (42.5)
   \>3                            28 (20.9)
  History of treatment            
   Chemotherapy                   89 (17.6)
   Operations                     43 (8.5)
   Radiation                      42 (8.3)
  Stage of breast cancer          
   Stage 0                        1 (0.7)
   Stage I                        44 (32.8)
   Stage II                       58 (43.3)
   Stage III                      24 (17.9)
   Stage IV                       6 (4.5)
   Unidentified                   1 (0.7)
  ER+                             132 (98.5)
  PR+                             97 (72.4)
  HER2+                           76 (56.7)
  Menopausal status               
   Premenopausal                  71 (53.0)
   Perimenopausal                 14 (10.4)
   Postmenopausal                 49 (36.6)

**Abbreviations:** TAM, tamoxifen; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.

###### 

Prevalence of *CYP2D6\*2*, *CYP2D6\*4*, *CYP2D6\*10*, and *CYP3A5\*3* in Thai breast cancer patients undergoing TAM treatment (N=134)

  Genotype (phenotype)      Prevalence (%)
  ------------------------- ----------------
  *CYP2D6*                  
   *CYP2D6\*1/\*1* (EM)     13 (9.7)
   *CYP2D6\*1/\*2* (EM)     3 (2.2)
   *CYP2D6\*2/\*2* (EM)     5 (3.7)
   *CYP2D6\*4/\*4* (PM)     2 (1.5)
   *CYP2D6\*1/\*10* (EM)    21 (15.7)
   *CYP2D6\*2/\*10* (EM)    13 (9.7)
   *CYP2D6\*4/\*10* (IM)    5 (3.7)
   *CYP2D6\*10/\*10* (IM)   72 (53.7)
  *CYP3A5*                  
   *CYP3A5\*1/\*1* (EM)     18 (13.4)
   *CYP3A5\*1/\*3* (EM)     64 (47.8)
   *CYP3A5\*3/\*3* (PM)     52 (38.8)

**Abbreviations:** TAM, tamoxifen; EM, extensive metabolizer; PM, poor metabolizer; IM, intermediate metabolizer.

###### 

Phenotype frequency (%) of *CYP2D6* with *CYP3A5* (N=134)

  *CYP2D6* phenotype   *CYP3A5* phenotype   Total (%)               
  -------------------- -------------------- ----------- ----------- -------------
  EM                   31 (23.1)            0 (0.0)     24 (17.9)   55 (41.0)
  IM                   51 (38.1)            0 (0.0)     26 (19.4)   77 (57.5)
  PM                   0 (0.0)              0 (0.0)     2 (1.5)     2 (1.5)
  Total (%)            82 (61.2)            0 (0.0)     52 (38.8)   134 (100.0)

**Abbreviations:** EM, extensive metabolizer; IM, intermediate metabolizer; PM, poor metabolizer.

###### 

Determination of the *CYP2D6\*4* allele from the *CYP2D6\*2* and *CYP2D6\*10* assays

  Patient   *CYP2D6* genotype                       
  --------- ------------------- ------------------- ------------------
  1         *CYP2D6\*1/\*2*     *CYP2D6\*10/\*10*   *CYP2D6\*4/\*10*
  2         *CYP2D6\*1/\*2*     *CYP2D6\*10/\*10*   *CYP2D6\*4/\*10*
  3         *CYP2D6\*1/\*2*     *CYP2D6\*10/\*10*   *CYP2D6\*4/\*10*
  4         *CYP2D6\*1/\*2*     *CYP2D6\*10/\*10*   *CYP2D6\*4/\*10*
  5         *CYP2D6\*1/\*2*     *CYP2D6\*10/\*10*   *CYP2D6\*4/\*10*
  6         *CYP2D6\*2/\*2*     *CYP2D6\*10/\*10*   *CYP2D6\*4/\*4*
  7         *CYP2D6\*2/\*2*     *CYP2D6\*10/\*10*   *CYP2D6\*4/\*4*

###### 

Prevalence of *CYP2D6* and *CYP3A5* polymorphisms in Caucasians and Thais

  Allele/genotype (phenotype)   Prevalence (%)   
  ----------------------------- ---------------- ------
  *CYP2D6*                                       
   *\*1* (wild type)            76.7             72.9
   *\*2* (wild type)            0.0              3.2
   *\*4* (null allele)          11.7             1.1
   *\*10* (reduced allele)      0.4              22.8
   *\*1/\*1* (EM)               63.9             9.7
   *\*1/\*2* (EM)               0.0              2.2
   *\*2/\*2* (EM)               0.0              3.7
   *\*1/\*4* (EM)               15.0             0.0
   *\*4/\*4* (PM)               1.5              1.5
   *\*2/\*4* (EM)               0.0              0.0
   *\*1/\*10* (EM)              0.0              15.7
   *\*2/\*10* (EM)              0.0              9.7
   *\*4/\*10* (IM)              0.75             3.7
   *\*10/\*10* (IM)             0.0              53.7
  *CYP3A5*                                       
   *\*1* (wild type)            2.2              37.3
   *\*3* (null allele)          97.8             62.7
   *\*1/\*1* (EM)               0.0              13.4
   *\*1/\*3* (EM)               4.4              47.8
   *\*3/\*3* (PM)               95.6             38.8

**Note:** Adapted from Copyright © 2013. *PLoS One*. Fernández-Santander A, Gaibar M, Novillo A, et al. Relationship between genotypes SULT1A2 and CYP2D6 and tamoxifen metabolism in breast cancer patients. 2013;8(7):e70183.[@b24-bctt-8-149] The phenotype classification in this table was defined by the authors of this article.

**Abbreviations:** EM, extensive metabolizer; IM, intermediate metabolizer; PM, poor metabolizer.
